Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer

Article

Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.

Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
MRI Guidance Can Tailor Neoadjuvant Chemo for HR-/HER2+ Breast Cancer

MRI Guidance Can Tailor Neoadjuvant Chemo for HR-/HER2+ Breast Cancer

May 14th 2024
Article

The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old

USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old

May 3rd 2024
Article

The final breast cancer screening recommendation from the United States Preventive Services Task Force advises that women aged 40 should begin biennial screening.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

ADCs Associated With Fatigue Among Patients With Breast Cancer

ADCs Associated With Fatigue Among Patients With Breast Cancer

April 29th 2024
Article

From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.

Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers

Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers

April 29th 2024
Article

Trastuzumab-strf was approved for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

© 2024 MJH Life Sciences

All rights reserved.